U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Titan Pharmaceuticals

Market Cap: US$5.6m

Does not have significant operations.

ProQR Therapeutics

Market Cap: US$251.8m

A biotechnology company, focuses on the discovery and development of novel therapeutic medicines.

Akanda

Market Cap: US$2.6m

Through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis-based products.

Cybin

Market Cap: US$141.1m

A clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions.

Perspective Therapeutics

Market Cap: US$262.9m

Develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.

Palvella Therapeutics

Market Cap: US$598.8m

A clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

Repligen

Market Cap: US$6.8b

A life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.

Seer

Market Cap: US$118.1m

A life sciences company, develops and commercializes products to decode the biology of the proteome.

Celldex Therapeutics

Market Cap: US$1.5b

A biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

Summit Therapeutics

Market Cap: US$17.7b

A biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies.

Bio-Rad Laboratories

Market Cap: US$7.6b

Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America.

Instil Bio

Market Cap: US$204.7m

A clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.

Rein Therapeutics

Market Cap: US$31.8m

A biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.

Aytu BioPharma

Market Cap: US$20.2m

A pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally.

Eli Lilly

Market Cap: US$666.9b

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.

BeOne Medicines

Market Cap: US$35.1b

An oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.

Rize Oncology

Market Cap: US$12.1m

A biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications.

Enlivex Therapeutics

Market Cap: US$25.5m

Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Journey Medical

Market Cap: US$185.7m

Focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.

Neumora Therapeutics

Market Cap: US$264.0m

A clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.

Tarsus Pharmaceuticals

Market Cap: US$2.4b

A commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.

CervoMed

Market Cap: US$94.5m

A a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.

Werewolf Therapeutics

Market Cap: US$61.7m

A biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions.

SenesTech

Market Cap: US$25.5m

Engages in the development and commercialization of a technology for managing animal pest populations through fertility control.

Mind Medicine (MindMed)

Market Cap: US$702.3m

A clinical stage biopharmaceutical company, develops novel products to treat brain health disorders.

Revium Rx

Market Cap: US$31.6m

A pre-clinical stage biopharmaceutical company, develops nano-liposomal particles (NLP) based pharmaceutical candidates.

Waters

Market Cap: US$17.8b

Provides analytical workflow solutions in Asia, the Americas, and Europe.

Edesa Biotech

Market Cap: US$17.8m

A clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases.

Benitec Biopharma

Market Cap: US$367.5m

A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.

Cyclerion Therapeutics

Market Cap: US$7.7m

A biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.

Earth Science Tech

Market Cap: US$59.3m

Together with its subsidies, focuses on health and wellness industry.

Mereo BioPharma Group

Market Cap: US$275.2m

A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally.

Cogent Biosciences

Market Cap: US$1.8b

A biotechnology company, focuses on developing precision therapies for genetically defined diseases.

Prime Medicine

Market Cap: US$445.7m

A biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States.

Genelux

Market Cap: US$129.9m

A clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

Arcellx

Market Cap: US$4.0b

Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.